Teriparatide
Brand name: Forteo
Rank #114 of 500 drugs by total cost
$153.9M
Total Cost
38,259
Total Claims
$153.9M
Total Cost
1,665
Prescribers
$4,024
Cost per Claim
1,051
Beneficiaries
39,714
30-Day Fills
$92K
Avg Cost/Provider
23
Avg Claims/Provider
About Teriparatide
Teriparatide (sold as Forteo) was prescribed 38,259 times by 1,665 Medicare Part D providers in 2023, costing the program $153.9M. At $4,024 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 111 | Lenvatinib Mesylate (Lenvima) | $164.6M | 7,004 |
| 112 | Treprostinil (Tyvaso Dpi) | $158.9M | 6,704 |
| 113 | Rimegepant Sulfate (Nurtec Odt) | $155.0M | 106,692 |
| 114 | Teriparatide (Forteo) | $153.9M | 38,259 |
| 115 | Ixekizumab (Taltz Autoinjector) | $149.8M | 19,972 |
| 116 | Sofosbuvir/Velpatasvir (Epclusa) | $149.4M | 6,544 |
| 117 | Dolutegravir/Rilpivirine (Juluca) | $148.9M | 41,081 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology